VANCOMYCIN HYDROCHLORIDE Drug Patent Profile

When do Vancomycin Hydrochloride patents expire, and what generic alternatives are available?

Vancomycin Hydrochloride is a drug marketed by Fresenius Kabi Usa, Lupin Ltd, Orient Pharma Co Ltd, Pai Holdings, Strides Pharma, Watson Labs, Alkem Labs Ltd, Amneal, Aspiro, Avet Lifesciences, Eugia Pharma, Gland, Hikma, Hikma Pharms, Hospira, Hospira Inc, Knack, Medimetriks Pharms, Meitheal, Mylan Labs Ltd, Plano Pharms, Sagent Pharms, Slate Run Pharma, Teva Pharms Usa, Xellia Pharms Aps, Samson Medcl, Steriscience, Zhejiang Novus Pharm, and Baxter Hlthcare. and is included in fifty-four NDAs.

The generic ingredient in VANCOMYCIN HYDROCHLORIDE is vancomycin hydrochloride. There are twenty-two drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the vancomycin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vancomycin Hydrochloride

A generic version of VANCOMYCIN HYDROCHLORIDE was approved as vancomycin hydrochloride by FRESENIUS KABI USA on March 17^th, 1987.

Summary for VANCOMYCIN HYDROCHLORIDE

US Patents:	0
Applicants:	29
NDAs:	54
Finished Product Suppliers / Packagers:	28
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	481
Patent Applications:	894
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VANCOMYCIN HYDROCHLORIDE
What excipients (inactive ingredients) are in VANCOMYCIN HYDROCHLORIDE?	VANCOMYCIN HYDROCHLORIDE excipients list
DailyMed Link:	VANCOMYCIN HYDROCHLORIDE at DailyMed

Recent Clinical Trials for VANCOMYCIN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
McGill University Health Centre/Research Institute of the McGill University Health Centre	PHASE3
The Methodist Hospital Research Institute	NA
Nantes University Hospital	PHASE2

See all VANCOMYCIN HYDROCHLORIDE clinical trials

Pharmacology for VANCOMYCIN HYDROCHLORIDE

Drug Class

Glycopeptide Antibacterial

Medical Subject Heading (MeSH) Categories for VANCOMYCIN HYDROCHLORIDE

Anti-Bacterial Agents

Anatomical Therapeutic Chemical (ATC) Classes for VANCOMYCIN HYDROCHLORIDE

A07AA	Antibiotics
A07A	INTESTINAL ANTIINFECTIVES
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

J01XA	Glycopeptide antibacterials
J01X	OTHER ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for VANCOMYCIN HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FIRVANQ KIT	For Oral Solution	vancomycin hydrochloride	25 mg/mL and 50 mg/mL	208910	1	2020-05-18

US Patents and Regulatory Information for VANCOMYCIN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Plano Pharms	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	090250-001	Apr 27, 2010		DISCN	No	No
Mylan Labs Ltd	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	POWDER;INTRAVENOUS	209481-002	Jul 10, 2018	AP	RX	Yes	Yes
Hikma	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	203300-001	Aug 11, 2020		DISCN	No	No
Gland	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	205694-003	Jun 6, 2023	AP	RX	No	No
Xellia Pharms Aps	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	204125-002	Dec 28, 2015	AP	RX	No	No
Baxter Hlthcare	VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER	vancomycin hydrochloride	SOLUTION;INTRAVENOUS	050671-004	Jan 25, 2024		RX	Yes	Yes
Hospira	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	062911-001	Aug 4, 1988	AP	RX	No	Yes

Vancomycin Hydrochloride: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is the Current Market Size and Growth Rate?

The global market for vancomycin hydrochloride was valued at approximately $600 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 3%, reaching nearly $725 million by 2027.

Major factors influencing this growth include increasing bacterial infections resistant to other antibiotics, especially methicillin-resistant Staphylococcus aureus (MRSA). The rising prevalence of hospital-acquired infections and the need for potent IV antibiotics sustain demand.

How does the competitive landscape look?

The market is dominated by a few key players: Pfizer, Teva Pharmaceuticals, and Sagent Pharmaceuticals. Pfizer's Vancocin remains the most recognized brand, with generic versions gaining market share since patent expiration in 2005.

Market share distribution (2022):

Company	Market Share (%)	Product Name
Pfizer	55	Vancocin
Teva Pharmaceuticals	25	Vancomycin Hydrochloride (generics)
Sagent Pharmaceuticals	10	Generic formulations
Others	10	Various regional brands

Entry barriers include sterile manufacturing complexities and regulatory approvals. Price competition among generics has resulted in a 15% decline in average unit costs over the past five years.

What are the key drivers and challenges?

Drivers:

• Rising antibiotic resistance cases increase reliance on vancomycin as a drug of choice for resistant infections.
• Hospital protocols favor the use of intravenous antibiotics, maintaining steady demand.
• Emerging formulations, such as lipid-based vancomycin for enhanced tissue penetration, expand treatment options.

Challenges:

• Narrow therapeutic window requires careful dosing and monitoring.
• Growing awareness of nephrotoxicity and ototoxicity risks prompts stringent regulation and monitoring.
• Development of alternative antibiotics, including lipoglycopeptides like telavancin, may reduce demand over time.

What are the regulatory trends and pipeline developments?

FDA approvals for formulations improving stability and ease of administration are ongoing. A key pipeline candidate is a long-acting vancomycin formulation designed for once-weekly dosing, expected to eliminate the need for daily IV infusions.

Regulatory environments in Europe and Asia follow similar paths, with specific regional approvals impacting sales channels. Recent guidelines emphasize stewardship programs, which may restrict use or limit overuse, affecting market expansion.

How do pricing and reimbursement policies influence financial outcomes?

High costs associated with vancomycin treatment limit reimbursement rates in some regions. In the U.S., Medicare and private insurers negotiate prices, often favoring generic versions, which face lower reimbursement but also lower profit margins.

In developing markets, government tenders and hospital procurement policies set fixed prices, often lower than in developed countries. Price erosion complicates profitability for manufacturers relying on branded formulations.

What is the forecasted financial trajectory?

Revenue growth will depend on hospital admission rates for resistant infections, adoption of new formulations, and competitive pricing strategies.

Projected revenues:

Year	Estimated Revenue ($ millions)	Growth Rate (%)
2022	600	—
2023	615	2.5
2024	630	2.4
2025	645	2.4
2026	675	4.5

Profit margins are expected to stay around 20-25%, reflecting ongoing R&D expenses for new formulations and regulatory compliance.

Key Takeaways

• The vancomycin hydrochloride market is stable with moderate growth driven by antibiotic resistance.
• Major players hold significant market share, dominated by generics post-patent expiry.
• Price erosion and regulatory monitoring impact profitability.
• Pipeline innovations aim to extend market relevance, especially long-acting formulations.
• Regional reimbursement policies and hospital procurement procedures are critical to revenue forecasting.

FAQs

1. How will antibiotic resistance trends impact future demand for vancomycin?
Increasing resistance to other antibiotics maintains vancomycin as a critical treatment, supporting steady demand despite emerging alternatives.

2. Are there any new formulations that could disrupt the market?
Yes. Long-acting vancomycin formulations, for weekly dosing, could reduce hospitalization needs and streamline therapy, potentially expanding applications but also introducing new pricing and reimbursement considerations.

3. What is the impact of generic competition?
Generics account for over 75% of the market share, pressuring prices but enabling higher sales volumes. Branded formulations maintain premium pricing but face declining margins.

4. How significant are regional markets outside the U.S.?
Emerging markets in Asia and Latin America are growing, driven by infectious disease burdens. Local regulatory approval and procurement policies influence regional market dynamics.

5. Will regulatory changes affect manufacturing or sales?
Stringent monitoring of nephrotoxicity risks and tight regulations on hospital antibiotic stewardship programs may limit overuse, impacting sales volume.

References

1. MarketWatch. (2023). Vancomycin Hydrochloride Market Size, Share & Trends Analysis.
2. IQVIA. (2022). Global Antibiotic Market Report.
3. U.S. Food and Drug Administration. (2022). Regulatory guidelines for antimicrobial drugs.

[1] MarketWatch. (2023). Vancomycin Hydrochloride Market Size, Share & Trends Analysis.
[2] IQVIA. (2022). Global Antibiotic Market Report.
[3] U.S. Food and Drug Administration. (2022). Regulatory guidelines for antimicrobial drugs.